Department of Cardiology, Royal Prince Alfred Hospital and NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Intern Med J. 2016 Aug;46(8):875-83. doi: 10.1111/imj.13093.
Inappropriate sinus tachycardia (IST) is an incompletely understood condition, characterised by an elevation in heart rate (HR) accompanied by wide ranging symptoms in the absence of an underlying physiological stimulus. The condition often takes a chronic course with significant adverse effects on quality of life. Currently, there is no effective treatment for IST. Beta-blockers, generally considered the cornerstone of treatment, are often ineffective and poorly tolerated. Ivabradine is a novel sinus node If 'funny current' inhibitor, which reduces the HR. It has been approved for the treatment of beta-blocker refractory chronic systolic heart failure and chronic stable angina but more recently has shown promise in the treatment of IST. This review provides an overview of IST prevalence and mechanisms followed by an examination of the evidence for the role and efficacy of ivabradine in the treatment of IST.
不适当窦性心动过速(IST)是一种尚未完全阐明的病症,其特征是在没有潜在生理刺激的情况下,心率(HR)升高,并伴有广泛的症状。该病症通常呈慢性病程,对生活质量有重大不良影响。目前,IST 尚无有效治疗方法。β受体阻滞剂通常被认为是治疗的基石,但往往无效且耐受性差。伊伐布雷定是一种新型窦房结 If“有趣电流”抑制剂,可降低 HR。它已被批准用于治疗β受体阻滞剂难治性慢性收缩性心力衰竭和慢性稳定型心绞痛,但最近在治疗 IST 方面显示出希望。本综述概述了 IST 的流行率和机制,然后检查了伊伐布雷定在治疗 IST 中的作用和疗效的证据。